We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Protective Antibodies for Malaria Identified by New Blood Test

By Labmedica staff writers
Posted on 13 Mar 2008
The malaria pathogen Plasmodium falciparum carries poisonous sugar molecules called glycosylosphatidylinositols (GPIs) on its surface that can be individually identified. More...
These sugar molecules are the dominant malarial toxins responsible for several pathologic processes associated with severe malaria. A person's immune system can form antibodies against these sugar molecules on the malaria pathogen, which protect against serious illness.

Blood samples taken from adults living in areas of Africa where malaria is endemic contain specific antibodies against particular GPIs. While infection is still possible despite the antibodies, the consequences are less serious. The immune system recognizes the poisonous sugar molecules as foreign bodies and blocks their toxic impact. Not living in high-risk areas, Europeans lack these antibodies. As soon as Europeans are infected with malaria, the number of antibodies increases significantly. Subsequently, there is a direct link between the amount of antibodies and protection against the disease.

A new blood test enables these antibodies to be detected. The method uses 64 pads comprising pinpoint dots affixed to glass slides. Every pad consists of several tiny heaps of different GPIs in varying concentrations. When blood serum is administered to such a pad, antibodies specifically bind to certain sugar molecules. Dyes then reveal to which GPIs the antibodies have become attached.

A chip developed in the laboratory of Prof. Peter Seeberger by a team of ETH Zurich and Swiss Tropical Institute (Zurich, Switzerland) scientists can use minute quantities of blood serum and sugar molecules to determine whether someone has formed particular antibodies against various GPIs. Large amounts of very pure GPIs can be produced synthetically in a laboratory, as the team demonstrated previously.

Using the information obtained from the chip, scientists can produce the specific sugar molecules that the immune system has to recognize. The findings should contribute to developing a sugar-based malaria vaccine and would be particularly beneficial to children in malaria-infested regions.

A report of the team's work was published online in the journal Nature Chemical Biology on March 2, 2008.


Related Links:
Swiss Tropical Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.